



CANCER PREVENTION &
RESEARCH INSTITUTE OF TEXAS

Company Commercialization Award Slate: \$23,408,151.00
November 2011

Application ID	Title	Primary Investigator	Entity	Recommended Award*
CC121004	Biobetter Cancer Monoclonal Antibody Program	Holtz, Richard	Caliber Biotherapeutics, a wholly owned Subsidiary of G-Con LLC	\$12,808,151.00
CC121020	Novel targeted biologics, Engineered Toxin Bodies (ETB), as cancer therapeutics	Kim, Jason	Molecular Templates, Inc.	\$10,600,000.00

*Subject to contract negotiations